Novel PTRH2::ALK Fusion in ALK-positive Histiocytosis Presenting as a Liver Abscess in an Infant: A Case Study - Top-Institutions - MDSpire

Novel PTRH2::ALK Fusion in ALK-positive Histiocytosis Presenting as a Liver Abscess in an Infant: A Case Study

By
Qian Wan
Hui Huang
Zhongjin Xu
Caihui Yuan
Yangyang Ma
Chongjun Wu
April 29, 2026
0 min

Frontiers In Immunology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

St. Jude Children's Research Hospital

Memphis, TN
Key Differentiators
- Pediatric Hematology-Oncology
- Molecular Pathology
- Pediatric Rare Cancers
#2

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Boston, MA
Key Differentiators
- Pediatric Hematology-Oncology
- Molecular Genetics
- Rare Pediatric Tumors
#3

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Hematology-Oncology
- Molecular Oncology
- Rare Cancers
#4

Children's Hospital of Philadelphia (CHOP)

Philadelphia, PA
Key Differentiators
- Pediatric Hematology-Oncology
- Molecular Diagnostics
- Rare Pediatric Diseases

Original Source(s)

Frontiers In Immunology

Novel PTRH2::ALK Fusion in ALK-positive Histiocytosis Presenting as a Liver Abscess in an Infant: A Case Study

by Qian Wan, Hui Huang, Zhongjin Xu, Caihui Yuan, Yangyang Ma, Chongjun Wu
April 29, 2026

Related Content

Frontiers In Oncology

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease

by Yuta Hasegawa, Takanori Teshima, Daigo Hashimoto
May 29, 2026

Frontiers In Oncology

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

by Yao Qiu, Xincai Zhao, Juan Chen, Manman Zhang, Yonggang Wang, Cheng Guo, Jianping Zhang, Rong Xu
May 29, 2026

Frontiers In Oncology

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer